Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Product Unit Size | Cost | Quantity | Stock |
|---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Cas No. | 1258595-14-0 |
|---|---|
| Purity | ≥99% |
| Formula | C29H32F2N3O7P |
| Formula Wt. | 603.56 |
| IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
| Synonym | LHC165 |
| Appearance | Pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
Oxazolidone derivative; Factor Xa inhibitor.
Peptide, used to study cell-surface binding; po...
Melatonin analog; MT1/2 agonist, 5-HT2C antagon...
5-HT3 antagonist.
Peptide, derivative of AT I, cleavage product o...
Bisphosphonate; FPPS inhibitor.
p53 activator, IMPDH and SIRT1 inhibitor.
Endogenous neuropeptide, somatostatin analog; s...
Na+ channel blocker.
Mixture of pyrantel, a thiophene, and pamoic ac...
Stable salt form of hyperforin, a compound foun...
Caspase 3 substrate.
Bufanolide steroid found in Bufo arenarum;VEGFR...
Antineoplastic immunomodulator.
Macrocyclic lactone.
SIRT1/2 inhibitor, indirect p53 activator.
FIASMA, 5-HT3 and σ1 agonist, SERT inhibitor.<...
Derivative of methyl caffeate, hydroxycinnamic ...
EGFR2 inhibitor.
Niacin derivative.